Rodent Models of AKI-CKD Transition

Overview

Journal Am J Physiol Renal Physiol

Publisher American Physiological Society

Specialties Nephrology
Physiology

Date 2018 Jun 28

PMID 29949392

Citations 113

Authors

Ying Fu

Chengyuan Tang

Juan Cai

Guochun Chen

Dongshan Zhang

Zheng Dong

Affiliations

Soon will be listed here.

Abstract

Acute kidney injury (AKI) is a contributing factor in the development and progression of chronic kidney disease (CKD). Despite rapid progresses, the mechanism underlying AKI-CKD transition remains largely unclear. Animal models recapitulating this process are crucial to the research of the pathophysiology of AKI-CKD transition and the development of effective therapeutics. In this review, we present the commonly used rodent models of AKI-CKD transition, including bilateral ischemia-reperfusion injury (IRI), unilateral IRI, unilateral IRI with contralateral nephrectomy, multiple episodes of IRI, and repeated treatment of low-dose cisplatin, diphtheria toxin, aristolochic acid, or folic acid. The main merits and pitfalls of these models are also discussed. This review provides helpful information for establishing reliable and clinically relevant models for studying post-AKI development of chronic renal pathologies and the progression to CKD.

Citing Articles

Oxidative stress and NRF2 signaling in kidney injury.

Ng C, Kim M, Yanti , Kwak M Toxicol Res. 2025; 41(2):131-147.

PMID: 40013079 PMC: 11850685. DOI: 10.1007/s43188-024-00272-x.

An adoptive cell therapy with TREM2-overexpressing macrophages mitigates the transition from acute kidney injury to chronic kidney disease.

Zhang Y, Liu Y, Luo S, Liang H, Guo C, Du Y Clin Transl Med. 2025; 15(3):e70252.

PMID: 40000418 PMC: 11859120. DOI: 10.1002/ctm2.70252.

Temporary bilateral clamping of renal arteries induces ischemia-reperfusion: A new pig model of acute kidney injury using total intravenous anesthesia.

Guilpin A, Magnin M, Aigle A, Ayoub J, Schuhler T, Lac R Physiol Rep. 2025; 13(3):e70203.

PMID: 39895016 PMC: 11788332. DOI: 10.14814/phy2.70203.

Butyrolactone I blocks the transition of acute kidney injury to chronic kidney disease in mice by targeting JAK1.

Zhang Z, Zhao Z, Qi C, Zhang X, Xiao Y, Chen C MedComm (2020). 2025; 6(2):e70064.

PMID: 39845897 PMC: 11751251. DOI: 10.1002/mco2.70064.

Panax Notoginseng Saponins Inhibit Apoptosis and Alleviate Renal Ischemia-Reperfusion Injury Through the ROCK2/NF-κB Pathway.

Xin L, Kanghao N, Jiacheng L, Xiaodong Y, Juhan Y, Xinyang Z Mol Biotechnol. 2025; .

PMID: 39820853 DOI: 10.1007/s12033-025-01366-z.

References

FINN W . Enhanced recovery from postischemic acute renal failure. Micropuncture studies in the rat. Circ Res. 1980; 46(3):440-8. DOI: 10.1161/01.res.46.3.440. View

Sharp C, Doll M, Megyesi J, Oropilla G, Beverly L, Siskind L . Subclinical kidney injury induced by repeated cisplatin administration results in progressive chronic kidney disease. Am J Physiol Renal Physiol. 2018; 315(1):F161-F172. PMC: 6087791. DOI: 10.1152/ajprenal.00636.2017. View

Jadot I, Colombaro V, Martin B, Habsch I, Botton O, Nortier J . Restored nitric oxide bioavailability reduces the severity of acute-to-chronic transition in a mouse model of aristolochic acid nephropathy. PLoS One. 2017; 12(8):e0183604. PMC: 5568239. DOI: 10.1371/journal.pone.0183604. View

Ravichandran K, Wang Q, Ozkok A, Jani A, Li H, He Z . CD4 T cell knockout does not protect against kidney injury and worsens cancer. J Mol Med (Berl). 2015; 94(4):443-55. DOI: 10.1007/s00109-015-1366-z. View

Yang L, Xing G, Wang L, Wu Y, Li S, Xu G . Acute kidney injury in China: a cross-sectional survey. Lancet. 2015; 386(10002):1465-71. DOI: 10.1016/S0140-6736(15)00344-X. View

Jiang C, Zhu W, Yan X, Shao Q, Xu B, Zhang M . Rescue therapy with Tanshinone IIA hinders transition of acute kidney injury to chronic kidney disease via targeting GSK3β. Sci Rep. 2016; 6:36698. PMC: 5114614. DOI: 10.1038/srep36698. View

Kapitsinou P, Haase V . Molecular mechanisms of ischemic preconditioning in the kidney. Am J Physiol Renal Physiol. 2015; 309(10):F821-34. PMC: 4652073. DOI: 10.1152/ajprenal.00224.2015. View

Menting T, Ergun M, Bruintjes M, Wever K, Lomme R, Goor H . Repeated remote ischemic preconditioning and isoflurane anesthesia in an experimental model of renal ischemia-reperfusion injury. BMC Anesthesiol. 2017; 17(1):14. PMC: 5273799. DOI: 10.1186/s12871-017-0310-x. View

Torres R, Velazquez H, Chang J, Levene M, Moeckel G, Desir G . Three-Dimensional Morphology by Multiphoton Microscopy with Clearing in a Model of Cisplatin-Induced CKD. J Am Soc Nephrol. 2015; 27(4):1102-12. PMC: 4814184. DOI: 10.1681/ASN.2015010079. View

10.

Pabla N, Dong G, Jiang M, Huang S, Kumar M, Messing R . Inhibition of PKCδ reduces cisplatin-induced nephrotoxicity without blocking chemotherapeutic efficacy in mouse models of cancer. J Clin Invest. 2011; 121(7):2709-22. PMC: 3223835. DOI: 10.1172/JCI45586. View

11.

Zager R, Johnson A, Becker K . Acute unilateral ischemic renal injury induces progressive renal inflammation, lipid accumulation, histone modification, and "end-stage" kidney disease. Am J Physiol Renal Physiol. 2011; 301(6):F1334-45. PMC: 3233867. DOI: 10.1152/ajprenal.00431.2011. View

12.

Humphreys B . Mechanisms of Renal Fibrosis. Annu Rev Physiol. 2017; 80:309-326. DOI: 10.1146/annurev-physiol-022516-034227. View

13.

Pabla N, Dong Z . Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int. 2008; 73(9):994-1007. DOI: 10.1038/sj.ki.5002786. View

14.

Grgic I, Campanholle G, Bijol V, Wang C, Sabbisetti V, Ichimura T . Targeted proximal tubule injury triggers interstitial fibrosis and glomerulosclerosis. Kidney Int. 2012; 82(2):172-83. PMC: 3480325. DOI: 10.1038/ki.2012.20. View

15.

He L, Wei Q, Liu J, Yi M, Liu Y, Liu H . AKI on CKD: heightened injury, suppressed repair, and the underlying mechanisms. Kidney Int. 2017; 92(5):1071-1083. PMC: 5683166. DOI: 10.1016/j.kint.2017.06.030. View

16.

Espandiari P, Rosenzweig B, Zhang J, Zhou Y, Schnackenberg L, Vaidya V . Age-related differences in susceptibility to cisplatin-induced renal toxicity. J Appl Toxicol. 2009; 30(2):172-82. PMC: 2829343. DOI: 10.1002/jat.1484. View

17.

Lu X, Li N, Shushakova N, Schmitt R, Menne J, Susnik N . C57BL/6 and 129/Sv mice: genetic difference to renal ischemia-reperfusion. J Nephrol. 2011; 25(5):738-43. DOI: 10.5301/jn.5000053. View

18.

Peng J, Li X, Zhang D, Chen J, Su Y, Smith S . Hyperglycemia, p53, and mitochondrial pathway of apoptosis are involved in the susceptibility of diabetic models to ischemic acute kidney injury. Kidney Int. 2014; 87(1):137-50. PMC: 4276728. DOI: 10.1038/ki.2014.226. View

19.

Dos Santos N, Rodrigues M, Martins N, Dos Santos A . Cisplatin-induced nephrotoxicity and targets of nephroprotection: an update. Arch Toxicol. 2012; 86(8):1233-50. DOI: 10.1007/s00204-012-0821-7. View

20.

Depierreux M, Van Damme B, Vanden Houte K, Vanherweghem J . Pathologic aspects of a newly described nephropathy related to the prolonged use of Chinese herbs. Am J Kidney Dis. 1994; 24(2):172-80. DOI: 10.1016/s0272-6386(12)80178-8. View